Author

J. F. Gainor

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1

Frequent Co-Authors

J. L. Barth· 2 shared A. Acker· 1 shared A. D. Cherniack· 1 shared A. Do· 1 shared A. Lawless· 1 shared A. N. Hata· 1 shared A. Shiba-Ishii· 1 shared A. Tirard· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. L. Barth

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor

S. M. Blum, D. A. Zlotoff, N. P. Smith, I. J. Kernin, S. Ramesh, L. Zubiri, J. Caplin, N. Samanta, S. C. Martin, A. Tirard, P. Sen, Y. Song, J. L. Barth, K. Slowikowski, M. Nasrallah, , A.-C. Villani

This study identifies immune cell types and biomarkers in irMyocarditis using single-cell RNA sequencing and TCR analysis across heart, blood, and tumor tissues.

bioRxiv · Sep 15, 2023 · PreprintImmunology

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, M. Mino-Kenudson, T. R. Johnson, P. Wei, S. L. Weinrich, M. A. McTigue, M. A. Walcott, L. Nguyen-Phuong, K. Dionne, A. Acker, L. Kiedrowski, A. Do, J. L. Peterson, , A. N. Hata

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Nature Cancer · Jun 20, 2022Peer-reviewedCancer Biology

High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1

W. Roh, Y. Geffen, M. Miller, S. Anand, J. Kim, D. Heiman, J. F. Gainor, P. W. Laird, A. D. Cherniack, National Cancer Institute Center for Cancer Genomics Tumor Molecular Pathology (TMP) AWG, G. Getz

The paper identifies five lung adenocarcinoma expression subtypes using consensus hierarchical clustering and finds subtype-specific dependencies on MET, CDK4, CDK6, and PD-L1, which could guide targeted therapies.

bioRxiv · Feb 20, 2022 · PreprintCancer Biology